These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 29495245)
21. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders. Shah U; Kowalski TJ Vitam Horm; 2010; 84():415-48. PubMed ID: 21094910 [TBL] [Abstract][Full Text] [Related]
22. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. Moritoh Y; Takeuchi K; Hazama M J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898 [TBL] [Abstract][Full Text] [Related]
23. AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes. Yoshida S; Tanaka H; Oshima H; Yamazaki T; Yonetoku Y; Ohishi T; Matsui T; Shibasaki M Biochem Biophys Res Commun; 2010 Oct; 400(4):745-51. PubMed ID: 20816753 [TBL] [Abstract][Full Text] [Related]
24. Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion. Yoshida S; Ohishi T; Matsui T; Shibasaki M Biochem Biophys Res Commun; 2010 Sep; 400(3):437-41. PubMed ID: 20804735 [TBL] [Abstract][Full Text] [Related]
33. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition. Chang E; Kim L; Choi JM; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Park DI; Park CY Metabolism; 2015 May; 64(5):633-41. PubMed ID: 25704082 [TBL] [Abstract][Full Text] [Related]
34. HD047703, a New Promising Anti-Diabetic Drug Candidate: In Vivo Preclinical Studies. Kim S; Kim DH; Kim YS; Ha TY; Yang J; Park SH; Jeong KW; Rhee JK Biomol Ther (Seoul); 2014 Sep; 22(5):400-5. PubMed ID: 25414769 [TBL] [Abstract][Full Text] [Related]
35. Contribution of intestinal dipeptidyl peptidase-4 inhibition for incretin-dependent improved glucose tolerance in mice. Yamashita S; Kawakami Y; Sato H; Sugitani S; Goto M; Kato N Eur J Pharmacol; 2019 Sep; 859():172521. PubMed ID: 31276666 [TBL] [Abstract][Full Text] [Related]
36. Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice. McKillop AM; Moran BM; Abdel-Wahab YH; Gormley NM; Flatt PR Diabetologia; 2016 Dec; 59(12):2674-2685. PubMed ID: 27677765 [TBL] [Abstract][Full Text] [Related]
37. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H Eur J Pharmacol; 2008 Jul; 588(2-3):325-32. PubMed ID: 18499100 [TBL] [Abstract][Full Text] [Related]